Keywords: USA, Multiple sclerosis, Emerging therapies, Merck KGaA, Cladribine, Novartis, Gilenya, Decision Resources

Attitudes of US relapsing-remitting multiple sclerosis patients to current and emerging therapies

Article | 06 December 2010

Print This

Less than 30% of surveyed relapsing-remitting multiple sclerosis (MS) patients in the USA indicate that they would request a switch to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in